NCT02246764View on ClinicalTrials.gov

Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

PHASE3CompletedINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Ocular HypertensionGlaucoma
Interventions
DRUG

AR-13324 Ophthalmic Solution 0.02%

1 drop once daily (QD), PM, OU

DRUG

AR-13324 Ophthalmic Solution 0.02% BID

1 drop BID, AM/PM, OU

DRUG

Timolol maleate Ophthalmic Solution 0.5% BID

1 drop BID, AM/PM, OU

OTHER

Placebo

1 drop QD, AM, OU

Trial Locations (1)

07921

Nancy Ramirez, Bedminster

Sponsors
All Listed Sponsors
lead

Aerie Pharmaceuticals

INDUSTRY

NCT02246764 - Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension | Biotech Hunter | Biotech Hunter